Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Ionis-Biogen Partnered Amyotrophic Lateral Sclerosis Trial Disappoints

Biogen Inc (NASDAQ:BIIB) and Ionis Pharmaceuticals Inc (NASDAQ:IONS) have announced topline results from the Phase 1 study of BIIB078 (IONIS-C9Rx) for C9orf72-associated amyotrophic lateral sclerosis (ALS).

  • In this Phase 1 study, BIIB078 was generally well-tolerated. The adverse events (AEs) were mostly mild to moderate in severity and occurred similarly across BIIB078 and placebo groups. 
  • The most common AEs were falls, procedural pain, and headache.
  • BIIB078 did not meet any secondary efficacy endpoints and did not demonstrate clinical benefit. 
  • In the dose cohorts up to 60 mg, there were no consistent differences between the BIIB078 and placebo groups. 
  • Participants in the BIIB078 90 mg dose cohort trended toward a greater decline than those in the placebo group across secondary endpoints. 
  • The companies have decided to discontinue the BIIB078 clinical development program, including its open-label extension study.
  • Biogen exercised its option to license BIIB115/ION306 from Ionis for spinal muscular atrophy (SMA).
  • Biogen made a one-time payment of $60 million to Ionis in Q4 FY21. 
  • Price Action: IONS shares are down 0.93% at $36.33, and BIIB stock is up 0.59% at $212.21 during the market session on the last check Monday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.